XML 9 R2.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 9,151 $ 5,530
Short-term investments 5,452 5,708
Prepaid expenses and other current assets 1,083 367
Total current assets 15,686 11,605
Property and equipment, net 130 167
Other assets 396 413
Total assets 16,212 12,185
Current liabilities:    
Accounts payable 1,536 1,419
Accrued clinical trial costs 1,103 1,141
Accrued expenses 1,143 1,468
Total current liabilities 3,782 4,028
Warrant liability 3,400 0
Total liabilities 7,182 4,028
Commitments and contingencies (Note 9)
Stockholders' equity    
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2024 and December 31, 2023, respectively; no shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 0 0
Common stock, $0.0001 par value; 500,000,000 shares authorized at September 30, 2024 and December 31, 2023; 10,761,917 and 5,754,505 issued and outstanding at September 30, 2024 and December 31, 2023, respectively 3 1
Additional paid-in capital 164,529 154,218
Accumulated deficit (155,506) (146,064)
Accumulated other comprehensive income 4 2
Total stockholders' equity 9,030 8,157
Total liabilities and stockholders' equity $ 16,212 $ 12,185